Effect of ursodeoxycholic acid combined with mossa bile in reflux gastritis
熊去氧胆酸联合莫沙胆汁反流性胃炎效果观察

摘要

目的 探讨在胆汁反流性胃炎治疗中联合运用熊去氧胆酸、莫沙必利的价值作用，评价其应用价值。方法 按照研究纳入标注与排除标准从2021年1月-2021年12月期间院内诊治的80例胆汁反流性胃炎患者纳入研究范围，编号1-80号，数字分组法分为两组，各40例，对照组接受莫沙必利单一用药治疗方案，实验组接受熊去氧胆酸、莫沙必利联合治疗方案，对比两组患者症状消失时间、治疗有效率以及用药不良反应。结果 在不同用药治疗方案实施后，实验组患者腹胀、恶心、呕吐等症状消失时间对比对照组明显缩短、治疗有效率对比更高，治疗后的病症复发率更低，差异对比有统计学意义（P<0.05）；两组患者接受不同治疗后相关不良反应发生风险数据信息之间无显著差异（P>0.05）。结论 在胆汁反流性胃炎治疗中联合运用熊去氧胆酸、莫沙必利，可对患者症状起到有效控制效果，让患者尽早康复，将整体治疗效果水平提升到了新高度，降低了患者病症的复发率，同时联合治疗方案安全性较高，有临床使用价值。

Abstract

Objective To explore the value of ursodeoxycholic acid combined with mosapride in the treatment of bile reflux gastritis and evaluate its application value.
Methods according to the inclusion and exclusion criteria of the study, 80 patients with bile reflux gastritis diagnosed and treated in the hospital from January 2021 to December 2021 were included in the study, numbered 1-80. They were divided into two groups by numerical grouping method, with 40 cases in each group. The control group received mosapride single drug treatment scheme, and the experimental group received ursodeoxycholic acid and Mosapride combined treatment scheme. The symptom disappearance time of the two groups were compared The effective rate of treatment and adverse drug reactions.
Results after the implementation of different drug treatment schemes, the disappearance time of abdominal distension, nausea, vomiting and other symptoms in the experimental group was significantly shorter than that in the control group, the treatment efficiency was higher, and the recurrence rate of the disease after treatment was lower. The difference was statistically significant (p<0.05); There was no significant difference between the two groups in the risk data of related adverse reactions after receiving different treatments (p>0.05).
Conclusion   the combined use of ursodeoxycholic acid and mosapride in the treatment of bile reflux gastritis can effectively control the symptoms of patients, enable patients to recover as soon as possible, raise the overall treatment effect to a new level, and reduce the recurrence rate of patients. At the same time, the combined treatment scheme is safe and has clinical value.